PHARMESIS INTERNATIONAL LTD.
(the "**Company**")
(Incorporated in the Republic of Singapore)
(Company Registration Number: 200309641E)

PROPOSED SUBSCRIPTION OF 3,000,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY
- COMPLETION OF SUBSCRIPTION AGREEMENT

---

1. The board of directors ("**Directors**") of the Company refers to the Company's announcements on 16 and 25 September 2015 (the "**Announcements**") relating to, *inter alia*, the entry into the Subscription Agreement. Unless otherwise defined, all capitalised terms used herein shall bear the meanings ascribed thereto in the Announcements.

2. Further to the Announcements, the Directors are pleased to announce that the Company has today allotted and issued the Subscription Shares to the Subscriber in accordance with the terms and conditions of the Subscription Agreement.

   The Subscription Shares rank *pari passu* in all respects with all existing Shares, except that they will not rank for any dividend, right, allotment or other distribution, the record date for which falls on or before completion of the Subscription ("**Completion**").

3. Following from the Completion, the total number of issued Shares has increased to 23,000,000 Shares. The Subscription Shares represent approximately 13.04% of the total issued share capital of the Company as at the date hereof.

4. The Subscription Shares are expected to be listed and quoted on the Main Board of the SGX-ST on or about 5 October 2015.

   The Approval-In-Principle is not to be taken as an indication of the merits of the Subscription, the Subscription Shares, the Company and/or its subsidiaries.

BY ORDER OF THE BOARD

Jiang Yun
Executive Chairman

2 October 2015